cAMPfield Therapeutics
PrivateLast Round
Series A
Jun 18, 2026
Total Funding Raised
$360M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
cAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for the treatment of inflammatory bowel disease (IBD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
cAMPfield Therapeutics Comparables
Compare cAMPfield Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Palisade Bio | 79% | |
| Abivax | 74% | |
| Ventyx Biosciences | 74% |
cAMPfield Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 18, 2026 | ||||
| Series A | May 20, 2026 |
cAMPfield Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longitude Capital | Series A |
| RA Capital Management | Series A |
| Mountainfield Venture Partners | Series A |
| Forbion | Series A |
| Deep Track Capital | Series A |
| Frazier Life Sciences | Series A |
| Abingworth | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 31, 2026
Open roles increased from 0 to 4, representing 80% of headcount.
- Jun 18, 2026
$180M round with participation from RA Capital Management.
cAMPfield Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about cAMPfield Therapeutics's valuation, stock price, and market status.
Is cAMPfield Therapeutics a public or private company?
cAMPfield Therapeutics is a private company.
What is the current stock price of cAMPfield Therapeutics?
cAMPfield Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is cAMPfield Therapeutics worth (valuation)?
Valuation information for cAMPfield Therapeutics is not publicly available.
Can I buy cAMPfield Therapeutics stock?
cAMPfield Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was cAMPfield Therapeutics's last funding round?
cAMPfield Therapeutics's most recent funding round was Series A on June 18, 2026.
Who are the main investors in cAMPfield Therapeutics?
Key investors in cAMPfield Therapeutics include Mountainfield Venture Partners, Frazier Life Sciences.
Will cAMPfield Therapeutics IPO soon?
No public IPO plans have been announced for cAMPfield Therapeutics.
How can I track cAMPfield Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor cAMPfield Therapeutics's secondary market activity and sign up for updates.